SCIENCE@home

Intraperitoneal chemotherapy in ovarian cancer treatment: are we missing something?

C. Marchetti

Published 2016 in Unknown venue

ABSTRACT

Pro intraperitoneal chemotherapy The rationale for administering chemotherapy directly into the peritoneal cavity is supported by preclinical, pharmacokinetic, and pharmacodynamics data. The most common route of ovarian cancer (OC) spread is within the peritoneal cavity. There are two potential explanations to clarify the efficacy of intraperitoneal (IP) chemotherapy. The first is the existence of the peritoneal-plasma barrier, a monolayer of mesothelial cells supported by a basement membrane and five layers of connective tissue. Due to this barrier, the IP delivery of anticancer agents may provide a pharmacokinetic gain by delivering drug levels that are 20-fold to 1,000-fold higher in the IP cavity than in plasma [1]. Second, the existence of cancer stem cells, which represent a subset of tumor cells efficient in self-renewal capacity [2]. In preclinical models, IP delivery of therapeutic agents has been shown to effectively eradicate OC stem cells [3-4]. In addition, three Gynecologic Oncology Group (GOG) multicenter, randomized, phase III clinical trials found IP chemotherapy to be superior to standard intravenous (IV) infusion in the primary medical management of small volume residual, advanced epithelial OC [5-7] (Table 1). Finally, in 2006, the National Cancer Institute (NCI) issued a rare Clinical Announcement encouraging the use of intraperitoneal and intravenous (IP/ IV) chemotherapy [8]. Therefore we can consider this approach as a possible standard treatment of advanced OC.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-14 of 14 references · Page 1 of 1

CITED BY

  • No citing papers are available for this paper.

Showing 0-0 of 0 citing papers · Page 1 of 1